Literature DB >> 16391262

Reconstruction of noncontained distal femoral defects with polymethylmethacrylate and crossed-screw augmentation: a biomechanical study.

Patrick C Toy1, Jeff France, R Lor Randall, Michael D Neel, Ronald I Shorr, Robert K Heck.   

Abstract

BACKGROUND: Curettage and cementation with polymethylmethacrylate are frequently used in the treatment of aggressive benign bone lesions such as giant-cell tumors, but strength and stiffness of the reconstructed bone have been concerns. This biomechanical study was undertaken to determine whether augmenting the cement with crossed screws would result in a stronger reconstruction.
METHODS: Large noncontained defects were created in the medial femoral condyles of twenty matched pairs of human cadavera. Four groups were organized to compare three types of reconstruction: (1) polymethylmethacrylate alone, (2) polymethylmethacrylate and intramedullary Steinmann pins, and (3) polymethylmethacrylate with crossed screws engaging the opposite cortex. The specimens were subjected to 2000 compressive cycles and were subsequently monotonically loaded to failure under a controlled displacement rate. Failure load and stiffness were determined for each femur that survived the cycling process.
RESULTS: Femora reconstructed with crossed screws and cement failed at higher loads and had greater stiffness than those reconstructed with cement alone (p = 0.025 and p = 0.0007) or cement augmented with intramedullary Steinmann pins (p = 0.019). Failure of femora reconstructed with cement and crossed screws occurred through an extra-articular transverse fracture, while failure in those with cement alone and cement with Steinmann pins occurred through an intra-articular (intercondylar) fracture.
CONCLUSIONS: In this in vitro cadaver study, augmentation of polymethylmethacrylate cement with crossed screws resulted in a stronger reconstruction of distal femoral tumor defects than that obtained with cement alone or with cement and intramedullary Steinmann pins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391262     DOI: 10.2106/JBJS.D.02313

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

1.  The Most Appropriate Reconstruction Method Following Giant Cell Tumor Curettage: A Biomechanical Approach.

Authors:  Azadeh Ghouchani; Mohammad H Ebrahimzadeh; Gholamreza Rouhi
Journal:  Arch Bone Jt Surg       Date:  2018-03

Review 2.  [Metastatic disease in long bones : Review of surgical treatment options].

Authors:  Franz Liska; Philipp Schmitz; Norbert Harrasser; Peter Prodinger; Hans Rechl; Rüdiger von Eisenhart-Rothe
Journal:  Unfallchirurg       Date:  2018-01       Impact factor: 1.000

3.  Clinical outcomes of extended intralesional curettage with cementation without implant augmentation in non-fracture giant cell tumor of bone around the knee.

Authors:  Sermsak Sukpanichyingyong; Krits Salang; Thananit Sangkomkamhang
Journal:  J Surg Case Rep       Date:  2022-04-30

4.  Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.

Authors:  Joseph Benevenia; Steven M Rivero; Jeffrey Moore; Joseph A Ippolito; Daniel A Siegerman; Kathleen S Beebe; Francis R Patterson
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

5.  Post-operative fracture risk assessment following tumor curettage in the distal femur: a hybrid in vitro and in silico biomechanical approach.

Authors:  Azadeh Ghouchani; Gholamreza Rouhi; Mohammad Hosein Ebrahimzadeh
Journal:  Sci Rep       Date:  2020-12-07       Impact factor: 4.379

6.  Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates.

Authors:  Xiuchun Yu; Ming Xu; Songfeng Xu; Qing Su
Journal:  Oncol Lett       Date:  2012-11-20       Impact factor: 2.967

Review 7.  The Great Need of a Biomechanical-Based Approach for Surgical Methods of Giant Cell Tumor: A Critical Review.

Authors:  Azadeh Ghouchani; Gholamreza Rouhi
Journal:  J Med Biol Eng       Date:  2017-06-22       Impact factor: 1.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.